Avadel Pharmaceuticals plc - Ordinary Share (AVDL)
AVDL moved a median of -0.16% 30 minutes after news, and -0.01% by the close. How AVDL actually reacts to news — the realized, point-in-time move the market made, measured across 246 labeled events over the last three years with zero look-ahead.
AVDL’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 48% | 217 |
| 30-min | -0.16% | 42% | 217 |
| 60-min | -0.21% | 45% | 217 |
| to close | -0.01% | 47% | 214 |
| Middle 50% of AVDL reactions | -1.20% to +0.74% |
|---|---|
| Median reaction (30-min) | -0.16% |
| Measured reactions | 246 |
Half of all Avadel Pharmaceuticals plc - Ordinary Share news events land between -1.20% and +0.74% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How AVDL reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 21 | -0.03% | 38% | +0.11% |
| Coverage initiations | 10 | -0.03% | 50% | 0.00% |
| Rating reiterations | 65 | -0.50% | 26% | -1.62% |
| Price-target raises | 14 | -0.21% | 43% | -1.51% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how AVDL ranks against every other measured name →
That’s how AVDL usually reacts — get an email when it moves on news →Email me when AVDL moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to AVDL's baseline. Nothing else.
Recent AVDL events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 15-12G AVADEL PHARMACEUTICALS | SEC filing · Form 15-12G | SEC EDGAR | — | — | |
| Form 8-K AVADEL PHARMACEUTICALS For: Feb 12 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form POS AM AVADEL PHARMACEUTICALS | SEC filing · Form POS | SEC EDGAR | — | — | |
| Form POSASR AVADEL PHARMACEUTICALS | SEC filing · Form POSASR | SEC EDGAR | — | — | |
| Form S-8 POS AVADEL PHARMACEUTICALS | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| Avadel Pharmaceuticals Announces Outcome of the Court Sanction Hearing | Press release | GlobeNewswire | +0.07% | -0.05% | |
| Form 8-K AVADEL PHARMACEUTICALS For: Jan 19 | SEC filing · Form 8-K | SEC EDGAR | +0.09% | +0.05% | |
| Avadel Pharmaceuticals Announces that Avadel Shareholders Approve the Proposed Acquisition by Alkermes | Press release | GlobeNewswire | +0.09% | +0.00% | |
| Form 8-K AVADEL PHARMACEUTICALS For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | +0.09% | +0.00% | |
| Form DEFA14A AVADEL PHARMACEUTICALS | SEC filing · Form DEFA14A | SEC EDGAR | +0.09% | +0.79% | |
| Avadel Pharmaceuticals Announces Completion of Enrollment in Phase 3 REVITALYZ™ Trial in Idiopathic Hypersomnia | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Form 8-K AVADEL PHARMACEUTICALS For: Dec 18 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.00% | |
| Form 8-K AVADEL PHARMACEUTICALS For: Dec 08 | SEC filing · Form 8-K | SEC EDGAR | +0.05% | +0.47% | |
| Form DEFA14A AVADEL PHARMACEUTICALS | SEC filing · Form DEFA14A | SEC EDGAR | +0.05% | +0.47% | |
| Announcement relating to despatch of Rule 15 proposal | Press release | GlobeNewswire | -0.05% | -0.14% | |
| Announcement relating to despatch of Definitive Proxy Statement and details of Scheme Meeting and Extraordinary General Meeting | Press release | GlobeNewswire | +0.00% | -0.02% | |
| Form DEFM14A AVADEL PHARMACEUTICALS | SEC filing · Form DEFM14A | SEC EDGAR | +0.00% | -0.02% | |
| Form PRER14A AVADEL PHARMACEUTICALS | SEC filing · Form PRER14A | SEC EDGAR | -0.14% | -0.47% | |
| Announcement relating to convening of Scheme Meeting and Extraordinary General Meeting | Press release | GlobeNewswire | -0.14% | -0.47% | |
| Form 8-K AVADEL PHARMACEUTICALS For: Nov 18 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.26% | |
| Form DEFA14A AVADEL PHARMACEUTICALS | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | +0.26% | |
| Avadel Board of Directors Declares Lundbeck Proposal a “Company Superior Proposal” | Press release | GlobeNewswire | +0.04% | -0.99% | |
| Form 8-K AVADEL PHARMACEUTICALS For: Nov 17 | SEC filing · Form 8-K | SEC EDGAR | +0.04% | -0.99% | |
| Form DEFA14A AVADEL PHARMACEUTICALS | SEC filing · Form DEFA14A | SEC EDGAR | +0.04% | -0.99% | |
| Avadel Receives Unsolicited Proposal from Lundbeck | Press release | GlobeNewswire | +0.25% | +1.33% | |
| Form 8-K AVADEL PHARMACEUTICALS For: Nov 14 | SEC filing · Form 8-K | SEC EDGAR | +0.25% | +1.33% | |
| Form DEFA14A AVADEL PHARMACEUTICALS | SEC filing · Form DEFA14A | SEC EDGAR | +0.25% | +1.33% | |
| Form PREM14A AVADEL PHARMACEUTICALS For: Nov 12 | SEC filing · Form PREM14A | SEC EDGAR | +0.39% | — | |
| FORM 8.1(a) & (b) - Avadel Pharmaceuticals plc | Press release | GlobeNewswire | +0.00% | +0.24% | |
| Avadel Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +0.27% | +0.32% | |
| Form 10-Q AVADEL PHARMACEUTICALS For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.27% | +0.32% | |
| Form 8-K AVADEL PHARMACEUTICALS For: Nov 04 | SEC filing · Form 8-K | SEC EDGAR | +0.27% | +0.32% | |
| Form DEFA14A AVADEL PHARMACEUTICALS | SEC filing · Form DEFA14A | SEC EDGAR | -0.05% | +0.11% | |
| Avadel Pharmaceuticals and Jazz Pharmaceuticals Reach Global Settlement | Press release | GlobeNewswire | -0.03% | +0.14% | |
| AVDL Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Avadel Pharmaceuticals plc Is Fair to Shareholders | Press release | Business Wire | -0.03% | +0.14% | |
| Form 8-K AVADEL PHARMACEUTICALS For: Oct 21 | SEC filing · Form 8-K | SEC EDGAR | -0.03% | +0.14% | |
| Form 8-K AVADEL PHARMACEUTICALS For: Oct 22 | SEC filing · Form 8-K | SEC EDGAR | -0.08% | +0.08% | |
| Form DEFA14A AVADEL PHARMACEUTICALS | SEC filing · Form DEFA14A | SEC EDGAR | -0.05% | +0.14% | |
| Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.07% | +1.20% | |
| Form 8-K AVADEL PHARMACEUTICALS For: Sep 15 | SEC filing · Form 8-K | SEC EDGAR | +2.17% | +1.49% | |
| Avadel Pharmaceuticals Celebrates Five Years of Driving Growth in Sleep Research Funding | Press release | GlobeNewswire | -0.13% | +1.65% | |
| Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.82% | -0.13% | |
| Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension at World Sleep 2025 | Press release | GlobeNewswire | +0.58% | +2.34% | |
| Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma Ltd | Press release | GlobeNewswire | -0.27% | +1.83% | |
| Form 8-K AVADEL PHARMACEUTICALS For: Aug 29 | SEC filing · Form 8-K | SEC EDGAR | -0.27% | +1.83% | |
| Avadel Pharmaceuticals to Present at Upcoming Investor Conferences | Press release | GlobeNewswire | -1.15% | +0.00% | |
| Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +1.25% | -0.70% | |
| Avadel Pharmaceuticals Reports Second Quarter 2025 Financial Results and Raises 2025 Revenue Guidance | Press release | GlobeNewswire | -11.32% | -9.00% | |
| Form 10-Q AVADEL PHARMACEUTICALS For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -11.32% | -9.00% | |
| Form 8-K AVADEL PHARMACEUTICALS For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | -11.32% | -9.00% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the AVDL section they belong to.
Where else AVDL is measured.
AVDL earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Heron Therapeutics, Inc. (HRTX) | 247 | -0.34% | 42% |
| Intra-Cellular Therapies Inc. (ITCI) | 247 | -0.04% | 44% |
| Cumberland Pharmaceuticals Inc. (CPIX) | 245 | 0.00% | 49% |
| electroCore, Inc. (ECOR) | 245 | 0.00% | 47% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Avadel Pharmaceuticals plc - Ordinary Share's median reaction calculated?
Every labeled AVDL news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 246 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 42% of AVDL's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does AVDL's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.